Marco Donia

Research interests

Publications

• Cutaneous melanoma: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up

  Annals of Oncology · 2024 · 10.1016/j.annonc.2024.11.006

• Targeting of multiple tumor-associated antigens by individual T cell receptors during successful cancer immunotherapy

  Cell · 2023 · 10.1016/j.cell.2023.06.020

• Tumor-Infiltrating Lymphocyte Therapy or Ipilimumab in Advanced Melanoma

  New England Journal of Medicine · 2022 · https://doi.org/10.1056/nejmoa2210233

• A phase 1/2 trial of an immune-modulatory vaccine against IDO/PD-L1 in combination with nivolumab in metastatic melanoma

  Nature Medicine · 2021 · 10.1038/s41591-021-01544-x

• Neoantigen-reactive CD8+ T cells affect clinical outcome of adoptive cell therapy with tumor-infiltrating lymphocytes in melanoma

  Journal of Clinical Investigation · 2021 · 10.1172/jci150535

• B Cells and Tertiary Lymphoid Structures: Friends or Foes in Cancer Immunotherapy?

  Clinical Cancer Research · 2021 · 10.1158/1078-0432.ccr-21-1130

• ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

  Annals of Oncology · 2020 · 10.1016/j.annonc.2020.07.004

• Tertiary lymphoid structures improve immunotherapy and survival in melanoma

  Nature · 2020 · https://doi.org/10.1038/s41586-019-1914-8

• Genome-wide CRISPR–Cas9 screening reveals ubiquitous T cell cancer targeting via the monomorphic MHC class I-related protein MR1

  Nature Immunology · 2020 · 10.1038/s41590-019-0578-8

• Collagen density regulates the activity of tumor-infiltrating T cells

  Journal for ImmunoTherapy of Cancer · 2019 · https://doi.org/10.1186/s40425-019-0556-6

• Principles of adoptive T cell therapy in cancer

  Seminars in Immunopathology · 2018 · 10.1007/s00281-018-0703-z

• Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model

  Nature Communications · 2017 · 10.1038/s41467-017-00786-z

• Mutational and putative neoantigen load predict clinical benefit of adoptive T cell therapy in melanoma

  Nature Communications · 2017 · https://doi.org/10.1038/s41467-017-01460-0

• Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen

  Clinical Cancer Research · 2016 · 10.1158/1078-0432.ccr-15-1879

• Targeting of cancer neoantigens with donor-derived T cell receptor repertoires

  Science · 2016 · 10.1126/science.aaf2288

• Large-scale detection of antigen-specific T cells using peptide-MHC-I multimers labeled with DNA barcodes

  Nature Biotechnology · 2016 · https://doi.org/10.1038/nbt.3662

• More tricks with tetramers: a practical guide to staining T cells with peptide– MHC multimers

  Immunology · 2015 · 10.1111/imm.12499

• Effector CD4 and CD8 T Cells and Their Role in the Tumor Microenvironment

  Cancer Microenvironment · 2012 · 10.1007/s12307-012-0127-6

• Adoptive cell therapy with autologous tumor infiltrating lymphocytes and low-dose Interleukin-2 in metastatic melanoma patients

  Journal of Translational Medicine · 2012 · 10.1186/1479-5876-10-169

• Dissection of T-cell Antigen Specificity in Human Melanoma

  Cancer Research · 2012 · 10.1158/0008-5472.can-11-2614

• Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging

  Aging · 2011 · 10.18632/aging.100296

• Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR Inhibitors: Rationale and Importance to Inhibiting These Pathways in Human Health

  Oncotarget · 2011 · 10.18632/oncotarget.240

• Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway

  Leukemia · 2011 · 10.1038/leu.2011.46

• Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy

  Leukemia · 2011 · 10.1038/leu.2011.66

• The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy

  Cell Cycle · 2010 · 10.4161/cc.9.9.11483

Current projects

No projects listed.